Slovenian Tourist Board published an article exploring the highlights in Slovenia 2026

LJUBLJANA, Slovenia, Dec. 10, 2025 (GLOBE NEWSWIRE) — In 2026, Slovenia invites travelers – and storytellers – to explore a year rich in cultural milestones, outdoor adventures and experiences that redefine slow, meaningful travel. With the Slovenian Tourist Board at the helm, the country showcases everything from a centuries-old passion play to world-class architecture, from […]

Slovenian Tourist Board published an article exploring the highlights in Slovenia 2026

Slovenian Tourist Board published an article exploring the highlights in Slovenia 2026 GlobeNewswire December 10, 2025 LJUBLJANA, Slovenia, Dec. 10, 2025 (GLOBE NEWSWIRE) — In 2026, Slovenia invites travelers – and storytellers – to explore a year rich in cultural milestones, outdoor adventures and experiences that redefine slow, meaningful travel. With the Slovenian Tourist Board

Rakovina Therapeutics Announces Upcoming Webinar with Variational AI

(TSX-V:RKV),(Boerse Frankfurt – Freiverkehr:7JO0), VANCOUVER, British Columbia, Dec. 10, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce that the Company will host a 60-minute webinar on December 17, 2025 at 10:00

Igyxos Biotherapeutics Announces Positive Results from Phase 1 Trial of IGX12, its First-in-Class Monoclonal Antibody for the Treatment of Male and Female Infertility

TOURS, France, Dec. 10, 2025 (GLOBE NEWSWIRE) — Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, today announced the successful completion of its Phase 1 clinical trial evaluation of IGX12. The recent Multiple Ascending Dose (MAD) Phase 1 trial of IGX12 was a randomised, placebo-controlled study in 14 healthy

CathVision Announces Appointment of Eric Thepaut as Independent Chairman of the Board and Releases ECGenius® System Version 3.5

CathVision, a medical technology company dedicated to improving clinical outcomes in cardiac electrophysiology through high-fidelity signal acquisition and intelligent software, today announced two major milestones: the appointment of Eric Thepaut as independent Chairman of the Board, and the commercial release of Version 3.5 of the ECGenius® System. https://mma.prnewswire.com/media/2842487/Eric_Thepaut.jpg Eric Thepaut Appointed Independent Chairman of the

Berlin Heals Welcomes Rob ten Hoedt as New Chairman of the Board

Berlin Heals Holding AG (Zug, Switzerland) is pleased to announce the appointment of Rob ten Hoedt as the new Chairman of the Board of Directors. https://mma.prnewswire.com/media/2622179/Berlin_Heals_Logo.jpg “We are thrilled to welcome someone of Rob ten Hoedt's caliber to the Board,” said Marko Bagaric, Co-founder and Member of the Board of Directors. “His global impact on

BON Unveils Kombucha-Inspired Product, Inks $12 Million Strategic Sales Agreement with Qingshengyuan

Bon Natural Life Limited (Nasdaq: BON) (“BON” or the “Company”), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced the launch of a new health-focused kombucha-inspired product and a strategic collaboration with Shaanxi Qingshengyuan Health Industry Co., Ltd. (“Qingshengyuan”), a leading distributor of functional health products in China focusing

Rakovina Therapeutics Announces Upcoming Webinar with Variational AI

Rakovina Therapeutics Announces Upcoming Webinar with Variational AI From Handshake to Breakthrough: How Rakovina & Variational AI Are Cracking the Code on CNS-Penetrant Cancer Therapies GlobeNewswire December 10, 2025 VANCOUVER, British Columbia, Dec. 10, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer

Igyxos Biotherapeutics Announces Positive Results from Phase 1 Trial of IGX12, its First-in-Class Monoclonal Antibody for the Treatment of Male and Female Infertility

Igyxos Biotherapeutics Announces Positive Results from Phase 1 Trial of IGX12, its First-in-Class Monoclonal Antibody for the Treatment of Male and Female Infertility GlobeNewswire December 10, 2025 TOURS, France, Dec. 10, 2025 (GLOBE NEWSWIRE) — Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, today announced the successful completion of

ZAKSIMLAB Expands Its Wellness Portfolio With Three New Fruit-Infused Kombuchas and Lemon Apple Cider Vinegar

Korean wellness beverage brandZAKSIMLAB is accelerating its presence in the functional drink market with the launch of three new fruit-infused kombucha flavors and a refreshed Lemon Apple Cider Vinegar drink. Under the slogan “Deliciously Healthy,” ZAKSIMLAB has built its identity around naturally fermented, clean-label functional drinks. Its signature kombucha line-which features probiotics from natural fermentation

Scroll to Top